Compare Gilead Sciences, Inc. (GILD) vs Alliant Energy Corporation (LNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Alliant Energy Corporation — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.40B), while Alliant Energy Corporation trades at $65.55 (market cap $16.99B). The key difference: Gilead Sciences, Inc. is far larger — about 10.7× Alliant Energy Corporation's market cap, and Alliant Energy Corporation pays the higher dividend (3.27%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Alliant Energy Corporation for 64 Days on average.
| GILD | LNT | |
|---|---|---|
Market Cap | $182.40B | $16.99B |
Volume | 4,469,821 | 2,488,387 |
Sector | Health | Utilities |
52-Week High | $155.80 | $78.03 |
52-Week Low | $116.74 | $63.21 |
Typical Hold Time | 111 Days | 64 Days |
Enterprise Value | $205.46B | $29.08B |
Dividend Yield | 2.23% | 3.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
LNT trades at $65.21, down 0.43% on the day, with a bullish technical signal despite mixed indicators. The company shows strong fundamentals with revenue growth to $4.36B in 2025 and net income of $810M, beating earnings estimates in three consecutive quarters. Analyst consensus is positive with a $77 price target and no sell ratings among 23 analysts. Recent news highlights institutional buying and a $13.4B capital investment plan supporting long-term growth.
LNT presents a favorable investment case with stable utility operations, consistent dividend growth, and strategic infrastructure investments. Key risks include rising debt levels (debt-to-asset ratio increased to 48.48% in 2025) and potential pressure from higher financing costs. The stock offers defensive value with a 3.29% dividend yield and exposure to growing data center demand in its service territories.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →
